Astellas Pharma, Inc./ US04623U1025 /
| 2024-07-26 9:51:50 PM | Chg. +0.2650 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 10.9950USD | +2.47% | 399,979 Turnover: 4.34 mill. |
-Bid Size: - | -Ask Size: - | 21.22 bill.USD | - | - |
Fundamentals
| FY 2022 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | 54.24 JPY | -19.14% |
| EPS Diluted: | - JPY | - |
| Revenues per Share: | - JPY | - |
| Book Value per Share: | - JPY | - |
| Cash Flow per Share: | - JPY | - |
| Dividend per Share: | - JPY | - |
| Total | in mill. | |
| Revenues: | 1,518,619.00 JPY | 17.16% |
| Net Income: | 98,714.00 JPY | -20.45% |
| Operating Cash Flow: | 327,767.00 JPY | - |
| Cash and Cash Equivalents: | 376,840.00 JPY | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | - | - |
| P/S Ratio: | - | - |
| P/BV ratio: | - | - |
| P/CF Ratio: | - | - |
| PEG: | - | - |
| Earnings Yield: | - | - |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | 21.22 bill. USD | 25.77 bill. USD |
| Free Float Market Cap.: | - USD | - USD |
| Market Cap. / Employee: | - USD | - USD |
| Shares Outstanding: | - | |
Profitability
| Gross Profit Margin: | 81.01% |
| EBIT Margin: | 8.76% |
| Net Profit Margin: | 6.50% |
| Return on Equity: | 6.55% |
| Return on Assets: | 4.02% |
Financial Strength
| Liquidity I / Cash Ratio: | 51.90% |
| Liquidity II / Quick Ratio: | 114.18% |
| Liquidity III / Current Ratio: | 144.62% |
| Debt / Equity Ratio: | 62.90% |
| Dynam. Debt / Equity Ratio: | 289.40% |
Efficiency
| Employees: | 14,480 |
| Personal Expenses / Employee: | - JPY |
| Revenues / Employee: | 104,877,002.76 JPY |
| Net Income / Employee: | 6,817,265.19 JPY |
| Total Assets / Employee: | 169,649,033.15 JPY |
| * Fiscal Year End: | 2023-03-31 |
| Accounting Standard: | IFRS |
| Currency: | JPY |
